Gesynta Pharma has announced the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis.

This strategically important decision follows a recent preclinical proof-of-concept study with GS-248 in an advanced model of endometriosis, where disease-modifying properties of the drug candidate were firmly established, states the company in a press release. These data together with the previously demonstrated favorable clinical safety profile of GS-248 and the significant unmet medical need form the basis for the decision to initiate preparations for a Phase II study in endometriosis, it states.

“The successful preclinical proof-of-concept study of GS-248 provides strong evidence of our drug candidate’s disease-modifying and pain-relieving ability. Together with previously accumulated clinical data pertaining to the drug candidate’s safety profile, pharmacokinetic properties and target inhibition, we have now established a solid scientific platform for advancing the development of GS-248 as a non-hormonal game-changer in the treatment of endometriosis,” says Patric Stenberg, CEO, Gesynta Pharma.

GS-248

GS-248 is a non-hormonal clinical-stage drug candidate targeting the pro-inflammatory enzyme mPGES-1, which via its product prostaglandin E2 plays a key role in inducing and maintaining endometriosis lesions.

In a recently conducted proof-of-concept study, GS-248 was evaluated in an advanced preclinical disease model of endometriosis. Results from this study show that the drug candidate markedly reduced the number of endometriosis lesions and had a positive impact on pain-related parameters and well-being.

Photo of Patric Stenberg: Gesynta